Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 10/20 | 0.37 |
| ▸ | F3 | P13726 | 4/20 | 0.37 |
| ▸ | F7 | P08709 | 2/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765753 | 0.88 | F2 (0.34) | F2F3F7PRSS1PRSS2 | |
| SCHEMBL23474398 | 0.87 | NTRK1 (0.44) | F2F3F7PRSS1MAPK1 | |
| SCHEMBL31558547 | 0.86 | PDE2A (0.41) | PDE2AF2F3PRSS1PRSS2 | |
| SCHEMBL30765665 | 0.86 | PDE2A (0.41) | PDE2AF2F3PRSS1PRSS2 | |
| SCHEMBL23460646 | 0.81 | F7 (0.49) | F2F3F7PRSS1MAPK1 | |
| SCHEMBL23460634 | 0.81 | F2 (0.53) | F2F3F7PRSS1PRSS2 | |
| SCHEMBL30765440 | 0.80 | F7 (0.39) | F2F3F7PRSS1MAPK1 | |
| SCHEMBL31558558 | 0.79 | PDE2A (0.41) | PDE2ABDKRB1 | |
| SCHEMBL31558417 | 0.79 | PDE2A (0.41) | PDE2ABDKRB1 | |
| Trifluoroacetic Acid SCHEMBL23496071 | 0.79 | F2 (0.51) | F2F3F7PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |